The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It is encouraging. However, there has not been a recent RNS confirming the outcome of the phase 1 dose escalation component and the advancement of the Phase 2 protocol. They are important developments, which would require an announcement by RNS.
In July, the CEO, Dr Craig Cook, said “we look forward to providing further updates as the development programme progresses”.
That is quite encouraging. It was said phase I would conclude Q3 of 2019 in an RNS back in July. As far I am aware (correct me if I'm wrong) they haven't released an RNS to say the results of phase I - however, the clinical trials say 'Phase 1 has completed sufficient safety assessments at highest dose level. Protocol for phase 2 expansion is ongoing'. Does that mean we can expect an RNS in future confirming this?
I assume the 'suspended' business means they are waiting for the go ahead to commence phase II, I don't think we should be too worried about that.
I just want to add to my last post. I know the word “suspended” doesn’t sound too optimistic. It gives the impression of gardening leave. However, I interpret the whole statement in a positive light. The protocol for the phase 2 efficacy study is in progress.
In July, Dr Sabine Mueller, Principal Investigator for the study said: "Midatech's MTX110 has shown promise as one of the most potent compounds against DIPG brain tumour cells in laboratory experiments. In this first in human study of MTX110 we are encouraged by the excellent safety profile so far and look forward to completing the safety evaluation and commencing the efficacy assessment of the drug later this year."
“Genuine hope is not blind optimism”. Although nothing is guaranteed, it appears to me that the possibility for further positive news is significant.
For example, in July 2019, the company announced that they were adding a further 3 patients to the Phase 1 component of the MTX110 clinical trial in order to confirm the Recommended Phase 2 Dose (RP2D). A further two higher dose levels were added to the study because MTX110 had been well tolerated. The recruitment status for the study has just been updated to:
“Suspended (Phase 1 has completed sufficient safety assessments at highest dose level. Protocol for phase 2 expansion is ongoing.)”
https://clinicaltrials.gov/ct2/show/NCT03566199
I'd say increasing one's position at this level should be a fairly safe bet. I took another tranche of shares at year end and now sitting on a mountain of shares waiting for more RNS and updates from the company. I suspect that 2020 will end up over time as a pivotal year in the history of the company. Time will tell, but for someone like me that's been here literally from the beginning this next 12 months should be "quite interesting" and I am idly sitting by waiting patiently for the turn.
Following recent positive news and the expectation of more to follow in 2020 I've just doubled by holding in Midatech. It's still only a relatively small holding because the future certainly isn't guaranteed but I remain very hopefull.
DYOR.